To evaluate the safety and efficacy of two doses of Cladribine in patients with Progressive MS.
Treatment of Progressive MS patients with Cladribine in a previous single-center, placebo-controlled clinical trial was associated with disease stabilization.
In the current study, 159 patients with a median baseline Kurtzke's Expanded Disability Status Scale (EDSS) score of 6.0 were randomly assigned to receive placebo or Cladribine.
0.07 mg/kg/day for 5 consecutive days every 4 weeks for either two or six cycles (total dose, 0.7 mg/kg or 2.1 mg/kg, respectively), followed by placebo, for a total of eight cycles.
Thirty percent had Primary/Progressive MS (PPMS) and 70% had Secondary/Progressive MS (SPMS).
EDSS and Scripps Neurologic Rating Scale (SNRS) scores were assessed bimonthly and MRI was performed every 6 months. The primary outcome measures was disability (mean change in EDSS).
Mean changes in disability did not differ among the groups at the end of the 12-month double-blind phase.
Both Cladribine treatments were superior to placebo for the proportion of patients having Gadolinium-enhanced T1
lesions and for the mean volume and number of such lesions (p ltoreq 0.003).
Differences were statistically significant at the 6-month evaluation time, with gtoreq90% reduction in volume and number of enhanced T1
lesions, which was maintained through final evaluation.
This effect segregated largely with the SPMS group. The T2 burden of disease showed a modest improvement in Cladribine-treated patients and worsened in placebo-treated patients. Most adverse events were mild or moderate in severity and not treatment limiting.
No significant treatment effects were found for Cladribine in terms of changes in EDSS or SNRS scores.
Both doses of Cladribine produced and sustained significant reductions in the presence, number, and volume of Gadolinium-enhanced T1
Brain lesions on MRI.
And, Cladribine 2.1 mg/kg reduced the accumulation of T2 lesion load. Cladribine at doses up to 2.1 mg/kg was generally safe and well tolerated.